Article
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
16 Mar 2023
Abstract excerpt
Chimeric antigen receptor (CAR) T-cell therapy has led to profound and durable tumor responses in a relevant subset of patients with relapsed/refractory (r/r) B-cell lymphomas. Still, some patients show insufficient benefit or relapse after CAR T-cell therapy. We performed a retrospective study to investigate the correlation between CAR T-cell persistence in the peripheral blood (PB) at 6 months, assessed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
